> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# GLP-1 medication use in US adults in 2025, including compounded versions and dose changes
- URL: https://www.coios.me/glp-1-medication-use-in-us-adults-in-2025-including/
- Published: 2026-11-15T11:45:21.000Z
- Updated: 2026-11-15T12:15:24.000Z
- Description: About one in 10 US adults reported past-year GLP-1 use, and 44% of users changed how they took it.
- Author: Daniel Ryan
- Tags: Health today, Obesity, diabetes and GLP-1, United States, #agency, #new, #item, #source-2026-11, #score-80

CDC's Rapid Surveys System questioned 8,118 US adults from two probability-based online panels in July–August 2025\. Overall, 9.8% reported past-year GLP-1 use, rising from 8.1% with overweight to 24.1% with severe (class 3) obesity. Use was 47.4% among adults who had ever had diabetes, against 5.7% among those who had not. Among the 976 users, 22.6% took a compounded version, more often women (27.3%) than men (14.8%). Some 44% modified prescribed use, mostly by skipping doses (28%), with 54% at ages 18–39 and 30% at ≥65\. Cumulative panel response rates were 13.3% and 3.8%, and all data were self-reported.

*Why it is interesting: It gives a national survey estimate of GLP-1 uptake, including use of products not reviewed by the FDA. Cost was cited by 58% of modifiers aged 18–39, against 20% of those aged 65 and over.*

Source

[MMWR. Morbidity and Mortality Weekly Report, 12 November 2026](https://doi.org/10.15585/mmwr.mm7544a1?ref=coios.me)

Paper

Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults - United States, 2025

Authors

Pierce SL, Balasuriya L, Kompaniyets L, Goodman AB

DOI

10.15585/mmwr.mm7544a1

Full text

[Open copy](https://pmc.ncbi.nlm.nih.gov/articles/PMC13759129/?ref=coios.me) (open-access copy, PubMed Central)

Type

Agency report

Design

Cross-sectional national survey, CDC Rapid Surveys System, US adults, July–August 2025

Verdict

New finding

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)